A pioneering breast cancer programme that scans DNA ‘barcodes’ for tailored treatments is set to benefit thousands of patients.
Cancer Research UK has awarded more than £1 million to the Personalised Breast Cancer Programme (PBCP) following the successful pilot phase.
Further funding from The Mark Foundation for Cancer Research, a US-based philanthropic organisation, will help the programme reach 2,000 patients.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The company is carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2.